Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials

An Open Label Extension Trial of Ublituximab and/or Umbralisib (TGR-1202) in Combination With Other Novel Agents or as Single Agents in Subjects Currently Receiving Treatment on a TG Therapeutics Study.

This is an open label compassionate use trial of Ublituximab and TGR-1202 in combination or as single agents in patients currently receiving treatment on Ublituximab and/or TGR-1202 trials with B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia.

Inclusion Criteria:

• Subjects must be currently receiving treatment with ublituximab and/or TGR-1202 on a previously approved protocol.
• Subjects must have completed at least 6 cycles of therapy on their current protocol.

Exclusion Criteria:

• Subject progressed while receiving therapy with ublituximab and/or TGR-1202 while participating in their immediate previous trial.